|
| Dosing | Tx reduces leiomyoma volume? | Used to treat leiomyoma in the US? |
|
Nonsteroidal anti-inflammatory drugs (NSAIDs) |
Ibuprofen | 600 mg orally daily starting on the first day of menstruation | No | Yes |
Mefenamic acid | 500 mg orally three times per day starting on the first day of menstruation | No | Yes |
Naproxen | 500 mg by mouth twice daily starting on the first day of menstruation | No | Yes |
|
Antifibrinolytics |
Tranexamic acid | 1.3 g orally three times per day for 5 days | No | Yes |
10 mg/kg iv (maximum 600 mg/dose) every 8 hours | No | Yes |
|
Combined contraceptives |
Oral, transdermal | No | Yes |
Cyclic or noncyclic | | |
|
Progestin-only therapies |
Norethindrone-contraceptive pills | 0.35 mg by mouth daily | No | Yes |
Levonorgestrel releasing intrauterine device (IUD) | Intrauterine placement by healthcare professional; lasts 3–5 years depending on the device | No | Yes |
Medroxyprogesterone (MPA) | Depo 150 mg intramuscularly every 12 weeks | No | Yes |
2.5–10 mg orally 12–14 days/month |
|
Aromatase inhibitors |
Letrozole | 2.5 mg orally for 12 weeks | Insufficient evidence | No |
|
Gonadotropin-releasing hormone (GnRH) analogs |
GnRH agonists | | | |
Leuprolide acetate | Depot 7.5 mg intramuscularly every month | Yes (30–65%), reversible | Yes |
Depot 22.5 mg intramuscularly every 3 months |
Depot 30 mg IM every 4 months |
Depot 45 mg IM every 6 months |
Eligard: 7.5 mg subcutaneously (sq) monthly/22.5 mg sq every 3 months/30 mg every 4 months/45 mg sq every 6 months | No |
Leuprolide acetate: 1 mg sq daily | No |
|
GnRH antagonists | | | |
Cetrorelix | 3 mg sq every 4 days | Yes, reversible | No |
Depot 60 mg sq on cycle day 2 |
|
Antiprogestins |
Mifepristone | 5–50 mg orally daily for 3–12 months | Insufficient evidence | No |
|
Selective Progesterone Receptor Modulators: |
Ulipristal acetate | 10–20 mg po daily for 3 months | Yes (12–53%), appears to be a stable reduction | No |
|